Helix BioPharma Reports Reduced Loss, Strengthens Cash Position Amid Strategic Financing

Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, today announced its financial results for the three- and nine-month periods ended April 30, 2026, highlighting a reduced net loss and a stronger cash position following a private placement.

The company reported a net and total comprehensive loss of $671,000 for the three months ended April 30, 2026, compared to $1.544 million in the same period last year. For the nine-month period, the loss was $2.374 million, down from $4.255 million a year earlier. The improvement was primarily due to lower research and development expenses and the conclusion of the LDOS006 clinical study, partially offset by increased operating, general, and administrative costs related to accounting, tax, legal, and consulting fees. Loss per share was $0.01 for the quarter and $0.03 for the nine months, versus $0.03 and $0.08 in the prior-year periods.

Cash and cash equivalents rose to $2.842 million as of April 30, 2026, from just $65,000 at the end of the prior fiscal year on July 31, 2025. The increase was largely driven by $3.673 million in proceeds from a private placement of unsecured convertible debentures, which closed subsequent to quarter-end. The debentures bear interest at 25% per annum, mature 14 months from the closing date (July 27, 2027), and are convertible at $1.42 per common share. As of April 30, 2026, the proceeds were recorded as subscription advances.

“Since the beginning of the year, our focus has been on securing the capital necessary to support Helix’s near-term operating and development objectives,” said Thomas Mehrling, MD, PhD, Chief Executive Officer. “With the successful completion of our recent private placement, we have made substantial progress toward our objective of establishing approximately twelve months of operating runway. This financing strengthens our ability to execute against our strategic priorities, including ongoing preparations for a U.S. exchange listing as we work to expand access to capital, advance L-DOS47 toward the clinic, and create long-term shareholder value.”

The company is actively evaluating financing and capital markets alternatives, including working with legal advisors on a base shelf prospectus and engaging with prospective investment banking partners. Additionally, Helix is assessing opportunities to broaden its investor base and increase access to U.S. capital markets, potentially through a future listing on a U.S. securities exchange.

Helix’s pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased therapy sensitivity. The company also advances pre-IND candidates LEUMUNA and GEMCEDA. The interim financial statements and MD&A are available on SEDAR+ at www.sedarplus.ca and on the company’s website at https://www.helixbiopharma.com/filings-and-financials/.

Forward-looking statements in this release involve risks and uncertainties, including those detailed in the company’s periodic filings on SEDAR+.